Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…
Top Research in Psoriatic Arthritis Presented at ACR Convergence 2024
Editor’s note: What research on psoriatic arthritis (PsA) presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. Dr. Pisetsky, a professor of medicine and immunology…
Systemic Lupus Erythematosus: A Complex, Multi-Challenging Disease
Reviewing the research presented at ACR Convergence 2024 WASHINGTON, D.C.—Despite significant advances that have taken place over the past several years, systemic lupus erythematosus (SLE) still presents great challenges to rheumatologists, given its unpredictable clinical course and the eventual consequences the disease itself and the complexity of its treatments impose on individual patients, their families…
AC&R Study Summary: Standardizing Treatment for Moderately Severe JDM
Why was this study done? Juvenile dermatomyositis (JDM) is the most common type of idiopathic inflammatory myopathy in childhood, and most patients have a chronic disease course requiring prolonged administration of systemic glucocorticoids and immunosuppressive agents. The initial management for patients with moderately severe JDM is relatively standardized, typically including methotrexate and systemic glucocorticoids with…
Cardiovascular & Cancer Risk Factors with JAK Inhibitors
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
Is Intestinal Dysbiosis Associated with RA?
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.
What the Joints Say: Challenges of Tender & Swollen Joint Count Differences
In a new study published in ACR Open Rheumatology, researchers evaluated the impact of tender-swollen joint difference on functional outcomes in early RA and whether associations vary by joint size.
Interventions to Delay RA Onset
Two new successful trials in abatacept, APIPPRA and ARIAA, are the first to convincingly demonstrate the potential of a preventive approach to RA treatment.
2024 Research Updates in ANCA-Associated & IgA Vasculitis
Summaries of selected research abstracts on ANCA-associated vasculitis & IgA vasculitis from the International Vasculitis Workshop.
3 AC&R Study Summaries: Lupus Fog, SSc Variance By Ethnicity & Tuberculosis Screening in New DMARD Users
Lupus Fog? By Laura C. Plantinga, PhD, Patricia P. Katz, PhD, S. Sam Lim, MD, MPH, C. Barrett Bowling, MD, MSPH, & Jinoos Yazdany, MD, MPH Why was this study done? Perceived cognitive impairment (i.e., lupus fog) is common in systemic lupus erythematosus (SLE). However, comprehensive, multidomain assessments of objective cognitive function are rarely performed….